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Edited by Stuart FergusonAbstract The evolutionary relationship of indoleamine 2,3-
dioxygenase (IDO) to some gastropod myoglobins suggests that
IDO may undergo autoxidation in vivo such that one or more
currently unidentiﬁed electron donors are required to maintain
IDO heme iron in the active, ferrous state. To evaluate this
hypothesis we have used yeast knockout mutants in combination
with a recently developed yeast growth assay for IDO activity
in vivo to demonstrate a role for cytochrome b5 and cytochrome
b5 reductase in maintaining IDO activity in vivo.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Indoleamine 2,3-dioxygenase (IDO; EC 1.13.11.42) is a
monomeric heme enzyme that is the ﬁrst and rate-limiting en-
zyme in mammalian tryptophan metabolism. IDO activity ac-
counts for the metabolism of 80% of non-protein tryptophan
metabolism in non-hepatic tissues [1]. In recent years, roles for
IDO have been identiﬁed in a number of immunological, neu-
rological and age-related human diseases [2–5]. IDO catalyzes
the oxidation of tryptophan to N-formylkynurenine by dioxy-
gen (Fig. 1). Fe(III)-IDO catalyzes this reaction if provided
with a source of superoxide anion radical, and formation of
an intermediate dioxygen adduct of Fe(II)-IDO has been pro-
posed [6,7]. While the IDO catalytic cycle is not yet well de-
ﬁned, presumably catalysis can proceed without the
participation of an additional electron source in contrast to
catalysis by cytochrome P-450 [8].
IDOhas been reported to be related evolutionarily tomyoglo-
bins of some gastropods [9]. This suggestion is consistent with
the observation that a stable dioxygen-bound adduct of IDO
can be prepared that exhibits an electronic spectrum identical
to that of oxymyoglobin [7] and with the conclusion that the
oxygenated intermediate of IDO autoxidizes with a rate con-
stant of 0.028 s1 (pH 7, 25 C) under steady-state conditions
in vitro [10]. Consequently, one means by which the activity of
IDO may be limited in vivo may be through the spontaneous
autoxidation that occurs in a manner analogous to that studied
in detail for autoxidation of oxymyoglobin and oxyhemoglobin*Corresponding author. Fax: +604 822 6860.
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doi:10.1016/j.febslet.2006.03.034[11]. Although the autoxidation of oxyhemoglobin in erythro-
cytes is relatively slow (3% each day [12]), the life time of eryth-
rocytes is suﬃciently long (120 days) that an enzymatic process
involving an erythrocytic form of cytochrome b5 and cyto-
chrome b5 reductase (i.e., methemoglobin reductase) has been
identiﬁed as a requirement for normal function of hemoglobin
[13]. By analogy, we propose that a similar process may be in-
volved in maintaining the activity of IDO in vivo.
To test this hypothesis, we report studies based on a yeast
growth assay that we have developed recently [14]. This assay
employs a yeast (Saccharomyces cerevisiae) tryptophan auxo-
troph transformed with a plasmid bearing the gene encoding
human IDO that results in expression of catalytically active
IDO. Expression of IDO in this yeast auxotroph renders the
growth of the organism dependent on the concentration of
tryptophan provided in the medium. In the current study, we
take advantage of the presence of a similar cytochrome
b5-cytochrome b5 reductase system in yeast (e.g., [15]) by mod-
ifying our growth assay strategy to determine the activity of
IDO in yeast knock-out mutants as a means of evaluating
the possible roles of cytochrome b5 and two yeast cytochrome
b5 reductases in promoting the activity of IDO in vivo.2. Materials and methods
Standard yeast media and molecular genetics protocols were used in
this work [16]. Yeast expression vector pARC25B, which contains a
Gal4 promoter and a Leu + marker, has been described elsewhere
[14]. All reagents were obtained from Aldrich except for bovine liver
catalase (Sigma, C-100).
The yeast deletion set (BY4741 MATa ura3D0 leu2D0 his3D1
met15D0) was obtained from Open Biosystems, and gene disruptions
were veriﬁed by analysis of genomic DNA by PCR. Yeast tryptophan
auxotrophs were produced by URA3 based conversion of the TRP1 lo-
cus using plasmid pNKY1009 [17]. The parental yeast strain has a
BY4741 MATa ura3D0 leu2D0 his3D1 met15D0 trp1Dura3 genotype.
The cDNA corresponding to the complete open reading frame of
IDO was ampliﬁed from a permanent human cell line [18] by PCR with
the following oligodeoxyribonucleotides: 5 0-CAAAAAATTGTTAA-
TATACCTCTATACTTTAACGTCAAGGGAATATAatggcacacgc-
tatggaaaactcctgg-3 0 and 5 0-CTTGCGGGGTTTTTCAGTATCTAC-
GATTCATAGATCTCTCGAGTTAaccttccttcaaaagggatttctcagttg-3 0
where the capitalized bases pair to the pARC25B vector and the bases
in lower case pair to the beginning and end of the IDO ORF. PCR
ampliﬁcation was carried out with VentR
 DNA polymerase (New
England BioLabs Inc.) according to the manufacturer’s instructions.
The PCR products were transformed into yeast with lithium acetate
and pARC25B linearized by BamHI and XHO. Transformed cells were
plated in minimum medium with 2% glucose without leucine and kept
at 30 C. Colonies were then checked for the correct construct byation of European Biochemical Societies.
Fig. 1. Reaction catalyzed by indoleamine 2,3 dioxygenase.
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erichia coli by standard procedures [14]. All constructs were sequenced
to verify the absence of random mutations.
The cDNA corresponding to the complete open reading frame of
IDO was PCR-ampliﬁed with the following oligodeoxyribonucleo-
tides: 5 0-cttatgacgcctgtgtgaaagctctggtctccctgaggagctacggtctgcaaatcg-30
and 5 0-CTTGCGGGGTTTTTCAGTATCTACGATTCATAGATC-
TCTCGAGTTAaccttcttcaaaaggg atttctcagttg-30 where the capitalized
bases pair to the pARC25B vector, the bases in lower case pair to the
IDO ORF, and the underlined bases introduce the His346Gly muta-
tion. PCR ampliﬁcation was carried out as indicated above. The
PCR products were transformed into yeast with lithium acetate and
IDO-pARC25B linearized by Bsu36i and XHO. Other procedures were
as indicated above. All constructs were sequenced to verify the pres-
ence of the desired mutation and absence of random mutations.
Growth assays of liquid cultures were performed as described previ-
ously [14] with minor modiﬁcations. Yeast strains containing IDO
(mutants or wild type) and empty vector (control) were grown over-
night in synthetic medium with 2% glucose and without leucine. The
following day, cells were washed twice with synthetic medium lacking
leucine, tryptophan and sugars and then diluted to a ﬁnal OD600 of
0.02 in synthetic medium with 2% galactose lacking leucine and tryp-
tophan. The diluted cells were added to 96-well (100 ll each) plates
containing varying amounts of tryptophan. After 40–45 h at 30 C,
plates were shaken to resuspend the cells inside the wells, and OD600
values were measured with a Tecan Sunrise plate reader. Growth
curves were determined in triplicate, and curves shown are averages
of three experiments.
Yeast cultures (40 h) were grown on synthetic medium with 2%
galactose, 2 mM tryptophan and without leucine. Cells were harvested
by centrifugation, and cell pellets were lysed with glass beads. Acid
washed glass beads (425–600 lm, Sigma, St. Louis, MO) and lysis buf-
fer (50 mM KPB, pH 6.5; 100 mM NaCl; 1 mM EDTA, 1· protease
inhibitor cocktail) were added to the cell pellets, followed by vortexing
three times for 7 min each, with 3 min incubations on ice in between.
Glass beads and cell debris were removed by centrifugation, and
protein extracts were quantiﬁed with the Bradford method (BioRad,
Hercules, CA).
IDO activity was determined as described elsewhere [13] with minor
modiﬁcations. The reaction mixture (1 ml) contained potassium phos-
phate buﬀer (50 mM, pH 6.5), ascorbic acid (20 mM), catalase
(200 mg/ml), methylene blue (10 mM), L-tryptophan (1 mM), and cell
lysate proteins (1 mg in 50 ll). The reaction was carried out at 37 C
for 30 min and stopped by the addition of trichloroacetic acid (200 ll
of a 30% (w/v) solution). After heating at 65 C for 15 min, the reac-
tion mixtures were centrifuged at maximum speed in a microcentrifuge
for 10 min, and the supernatant ﬂuid was mixed with p-dimethylami-
nobenzaldehyde in acetic acid (1.2 ml of 2% (w/v) solution) to convert
any kynurenine present to a yellow product. The amount of this prod-
uct was monitored at 480 nm as a measure of IDO activity.
Polyclonal anti-IDO antiserum was obtained by immunizing New
Zealand White rabbits with puriﬁed recombinant human IDO (lacking
the His6-tag) and was used at 1:10000 dilution. Western blots were pre-
pared by standard procedures involving 10% SDS–PAGE of cell lysate
(100 lg), transferring to nitrocellulose membranes and blotting. For
detection of IDO, anti-mouse Ig horseradish peroxidase conjugated
antibody (Amersham Bioscience, Piscataway, NJ) was used at a dilu-
tion of 1:100000 followed by ECL (Amersham Bioscience), and expo-
sure to X-ray ﬁlm.Fig. 2. Growth of yeast cultures expressing (A) wild-type IDO and (B)
the His356Gly IDO variant in the presence of 2% galactose. Growth of
yeast (40 h) transformed with an expression vector lacking (s) and
possessing (d) the gene encoding WT or the variant IDO are shown.
Error bars indicate the standard deviation determined from triplicate
analyses.3. Results
Our original assay for IDO activity in vivo employed a yeast
tryptophan auxotroph with a genomically integrated copy ofthe gene encoding human IDO [14] while the current protocol
involves growth of a yeast tryptophan auxotroph expressing
IDO from a plasmid. Nevertheless, the growth of this yeast
strain also exhibits a signiﬁcantly greater dependence on the
concentration of Trp in the medium than control cells
(Fig. 2A). Cultures of cells (100 lM Trp) bearing the IDO gene
or the empty vector exhibit a diﬀerence in OD600 of
0.493 ± 0.006 after 40 h growth. Expression of the inactive
IDO variant has virtually no inﬂuence on yeast growth
(Fig. 2B), so the activity of the enzyme and not simply the
expression of the protein is the basis for the eﬀect of IDO
expression on yeast growth observed in Fig. 2A. On the other
hand, cultures of yeast lacking the gene encoding cytochrome
b5 exhibit a decrease in OD600 of just 0.12 ± 0.01 (at 100 lM
Trp) when they also express IDO (Fig. 3). In other words, re-
moval of the cytochrome b5 gene from the yeast genome re-
duced IDO activity by 75% as detected by this method.
The amount of IDO expressed in these various cell lines as
determined by Western blots was essentially identical
(Fig. 4), and IDO activity assays of yeast lysates (in the pres-
ence of excess ascorbate as a external reducing agent) pro-
duced identical results (data not shown). These ﬁndings
establish that the intracellular concentrations of active IDO
are essentially identical in both cell lines expressing this en-
zyme. While the occurrence of endogenous IDO or related
activity in yeast is uncertain, we note that our anti-serum
against human IDO fails to cross-react with any yeast protein
(Fig. 4). Moreover, the growth characteristics of the control
cultures lacking a gene encoding human IDO or transformed
with a plasmid bearing an inactive human IDO variant would
account for any inﬂuence than an endogenous IDO activity
might contribute to the current results.
Fig. 5. Eﬀect of IDO expression on growth of yeast mutants lacking
mitochondrial or endoplasmic reticular forms of cytochrome b5
reductase in the presence of 2% galactose. (A) YKL150W (MCR1)
deletion mutant and (B) YIL043C (CBR1) deletion mutant yeast cells
transformed (d) with the IDO expression vector or transformed (s)
with the same vector lacking the gene for IDO. Error bars indicate the
standard deviation determined from triplicate analyses.
Fig. 3. Eﬀect of IDO expression on growth of a yeast mutant lacking
cytochrome b5. Growth of yeast (40 h) transformed with an expression
vector lacking (s) and possessing (d) the gene encoding WT IDO are
shown. Error bars indicate the standard deviation determined from
triplicate analyses.
Fig. 4. Western blot of the yeast strain lysates. (A) parental yeast cells
with pARC25B, (B) parental yeast cell + IDO, (C) cytochrome b5
deletion mutant + IDO, (D) YKL150W deletion mutant with IDO,
and (E) YIL043C deletion mutant with IDO. pARC25B is the empty
vector control. As reported in related experiments previously [14],
these bands all exhibited mobilities consistent with a molecular weight
of 45 kDa as indicated by standards.
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cytochrome b5 reductase should exert a similar eﬀect. To eval-
uate this possibility, we studied the growth of yeast strains lack-
ing either the mitochondrial form (MCR1) of cytochrome b5
reductase (YKL150W) or the endoplasmic reticular form
(CBR1) of the reductase (YIL043C) (Fig. 5). The results of this
experiment indicate that deletion of the gene encoding the mito-
chondrial reductase has a much smaller eﬀect on the growth
inhibition resulting from expression of IDO (Fig. 5A) than does
deletion of the gene encoding the endoplasmic reticular form of
the reductase (Fig. 5B). This diﬀerential eﬀect of the two reduc-
tases is consistent with our previous observation that IDO ex-
pressed in yeast is located primarily in the yeast cytoplasm
[14]. Again, Western blot analysis (Fig. 2) indicates that the
intracellular concentration of IDO present in these yeast strains
is comparable in all yeast strains studied in this work.4. Discussion
We have shown previously that human IDO expressed from a
cassette integrated into the genomic Lys2 locus of S. cerevisiae is
active, that this IDO is located primarily in the cytoplasm, and
that the eﬀect of IDO expression on yeast growth can be used
to search for novel inhibitors of IDO that function in vivo [14].
The present study demonstrates that human IDO expressed
from a non-integrated yeast vector is also active in vivo and that
a yeast tryptophan auxotroph expressing human IDO exhibits
growth inhibition relative to identical yeast transformed with
the same vector but lacking the IDO gene (Fig. 2A).
The current study establishes that a similar strategy used in
combination with yeast knock-out mutants provides an
instructive means of evaluating physiological factors that
may inﬂuence IDO activity. The reduction of sensitivity of
yeast growth to the expression of active IDO resulting from
lack of cytochrome b5 and the endoplasmic cytochrome b5
reductase provides compelling evidence that this cytochrome
and its reductase can function in maintaining the activity of
IDO in vivo. Notably, sensitivity of yeast growth to the expres-
sion of IDO was signiﬁcantly less for the yeast mutant unable
to produce the endoplasmic reductase than was observed for
yeast unable to produce the mitochondrial reductase.
While the absence of the cytochrome or the reductase signif-
icantly reduces the growth inhibition resulting from IDO
expression, the absence of neither protein completely elimi-
nates the eﬀect of IDO. Presumably, in the absence of these
proteins either the autoxidation of IDO occurs at a suﬃciently
slow rate that culture growth continues to be inﬂuenced by
IDO to the extent observed or alternative sources of electrons
remain that have not yet been identiﬁed. One alternative
source of electrons could be NADPH-cytochrome P-450 oxi-
doreductase. Disruption of cytochrome b5 generates no growth
phenotype in a wild-type background but results in lethality
when present in yeast also lacking NADPH-cytochrome
P-450 oxidoreductase. Thus, NADPH-cytochrome P-450
oxidoreductase might compensate partially for the absence of
cytochrome b5 [15,19]. In view of the ability of Fe(III)-IDO
to use superoxide anion radical as a substrate, another enzyme
with potential consequences for activity of IDO in vivo is
superoxide dismutase. As for NADPH-cytochrome P-450
oxidoreductase, the functional consequences of eliminating
superoxide dismutase on yeast physiology are suﬃciently pro-
2268 E. Vottero et al. / FEBS Letters 580 (2006) 2265–2268found that the functional relationship between SOD and IDO
in vivo will not be easily resolved through experiments of the
type described here.
Nevertheless, the present results provide the ﬁrst indication
that an electron donor for IDO may be present in vivo. The
implied value of an enzymatic means of overcoming the eﬀects
of autoxidation and maintaining IDO in the functional, re-
duced state as believed to occur with myoglobin and hemoglo-
bin further supports the evolutionary relationship of IDO to
the globin family [9].
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